Article
Immunology
Phoom Narongkiatikhun, Kajohnsak Noppakun, Romanee Chaiwarith, Poramed Winichakoon, Surachet Vongsanim, Yuttitham Suteeka, Karn Pongsuwan, Prit Kusirisin, Nuttanun Wongsarikan, Kanda Fanhchaksai, Chantana Khamwan, Dararat Dankai, Vuddhidej Ophascharoensuk
Summary: This study assessed the immunogenicity and safety of different vaccine regimens in patients with chronic kidney disease. The results showed that heterologous vaccine prime-boost was more effective in inducing an immune response, and no serious adverse events were reported.
Article
Biotechnology & Applied Microbiology
Guy Cohen, Pawornrath Jungsomsri, Jirath Sangwongwanich, Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Kasiruck Wittayasak, Nawarat Thonwirak, Kamonwan Soonklang, Gaidganok Sornsamdang, Chirayu Auewarakul, Nithi Mahanonda
Summary: Mass vaccination with a safe and effective vaccine may be the best approach to control the COVID-19 pandemic. This study found that a heterologous prime-boost strategy with CoronaVac and AZD1222 vaccines resulted in a stronger immune response compared to a homologous prime-boost strategy with CoronaVac alone. The order of vaccine administration was also found to be important, with the CoronaVac/AZD1222 combination eliciting higher immunogenicity.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Immunology
Davide Firinu, Andrea Perra, Marcello Campagna, Roberto Littera, Federico Meloni, Francesca Sedda, Maria Conti, Giulia Costanzo, Monica Erbi, Gianmario Usai, Carlotta Locci, Mauro Giovanni Carta, Riccardo Cappai, Germano Orru, Stefano Del Giacco, Ferdinando Coghe, Luchino Chessa
Summary: The study showed that the IgG anti-S-RBD levels in the ChAd/BNT vaccine regimen were significantly higher compared to other vaccine schedules, supporting the current national guidelines for heterologous boosting.
Article
Immunology
Louise Benning, Maximilian Toellner, Asa Hidmark, Matthias Schaier, Christian Nusshag, Florian Kaelble, Paula Reichel, Mirabel Buylaert, Julia Grenz, Gerald Ponath, Katrin Klein, Martin Zeier, Caner Susal, Paul Schnitzler, Christian Morath, Claudius Speer
Summary: This study demonstrates that heterologous ChAdOx1 nCoV-19/BNT162b2 vaccination is safe and induces a strong and broad humoral response in healthy individuals.
Article
Immunology
Chang Chu, Anne Schoenbrunn, Dorothea Fischer, Yvonne Liu, Johann-Georg Hocher, Jutta Weinerth, Kristin Klemm, Volker von Baehr, Bernhard K. Kraemer, Saban Elitok, Berthold Hocher
Summary: Due to rare but major adverse reactions, German health authorities recommended a heterologous booster vaccination (ChAd-BNT) for adults under 60 who received the AstraZeneca adenoviral vaccine (ChAd). Comparisons between the heterologous (ChAd-BNT) and homologous (BNT-BNT) vaccination regimens showed enhanced humoral and cellular immune responses in healthy controls, with neutralizing antibodies being higher after heterologous immunization. Immunocompromised patients, such as dialysis patients, benefitted more from the heterologous vaccination, showing adequate immune responses. Tumor and rheumatic patients also showed some benefits from the heterologous immunization, although to a lesser extent than dialysis patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Jinnam Kim, Changhyup Kim, Jung Ah Lee, Se Ju Lee, Ki Hyun Lee, Jung Ho Kim, Jin Young Ahn, Su Jin Jeong, Nam Su Ku, Joon-Sup Yeom, Young Goo Song, Jun Yong Choi
Summary: This study investigated the immune response and reactogenicity to the ChAdOx1 nCoV-19 vaccine based on pre-existing adenovirus immunity. It found that individuals without pre-existing adenovirus immunity showed a higher immune response and a higher frequency of reactogenicity to the ChAdOx1 nCoV-19 vaccination.
Article
Immunology
Yves Michiels, Nadhira Houhou-Fidouh, Gilles Collin, Jerome Berger, Evelyne Kohli
Summary: The study demonstrated that a MS patient treated with teriflunomide showed a strong humoral response after receiving a ChAdOx1 nCoV-19/ BNT162b2 vaccination regimen, indicating that the medication did not hinder the development of an effective immune response to the vaccine.
Article
Clinical Neurology
Frederic Zuhorn, Tilmann Graf, Randolf Klingebiel, Wolf-Rudiger Schabitz, Andreas Rogalewski
Summary: The global COVID-19 pandemic has caused millions of infections and deaths worldwide, leading to unprecedented efforts in vaccine development. The use of corticosteroids for immunosuppressive therapy has shown efficacy in patients with postvaccinal encephalitis.
ANNALS OF NEUROLOGY
(2021)
Article
Immunology
Wisit Prasithsirikul, Tanawin Nopsopon, Phanupong Phutrakool, Pawita Suwanwattana, Piyawat Kantagowit, Wannarat Pongpirul, Anan Jongkaewwattana, Krit Pongpirul
Summary: This study investigated the immunogenicity of ChAdOx1 nCoV-19 vaccination and the immune response after COVID-19 infection in ESRD patients receiving HD. The results showed a significant increase in anti-spike IgG levels after two-shot vaccination, followed by a decrease after 3 months. However, the levels of anti-spike IgG remained stable in the post-recovery group. There was no significant difference in the change of anti-spike IgG between the one-shot vaccinated and post-recovery groups.
Article
Medicine, General & Internal
Jie Wei, Weiya Zhang, Michael Doherty, Zachary S. Wallace, Jeffrey A. Sparks, Na Lu, Xiaoxiao Li, Chao Zeng, Guanghua Lei, Yuqing Zhang
Summary: In a population-based study in the UK, the BNT162b2 vaccine showed higher efficacy than the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection and hospitalization for COVID-19, but there was no significant difference in the risk of death from COVID-19.
Article
Medicine, General & Internal
Karen J. Hager, Gonzalo Perez Marc, Philipe Gobeil, Ricardo S. Diaz, Gretchen Heizer, Conrado Llapur, Alexander I. Makarkov, Eduardo Vasconcellos, Stephane Pillet, Fernando Riera, Pooja Saxena, Priscila Geller Wolff, Kapil Bhutada, Garry Wallace, Hessam Aazami, Christine E. Jones, Fernando P. Polack, Luciana Ferrara, Judith Atkins, Iohann Boulay, Jiwanjeet Dhaliwall, Nathalie Charland, Manon M. J. Couture, Julia Jiang-Wright, Nathalie Landry, Sophie Lapointe, Aurelien Lorin, Asif Mahmood, Lawrence H. Moulton, Emily Pahmer, Julie Parent, Annie Seguin, Luan Tran, Thomas Breuer, Maria-Angeles Ceregido, Marguerite Koutsoukos, Francois Roman, Junya Namba, Marc-Andre D'Aoust, Sonia Trepanier, Yosuke Kimura, Brian J. Ward
Summary: The CoVLP+AS03 vaccine showed efficacy in preventing Covid-19 caused by different variants, with efficacy ranging from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Microbiology
Sana Eybpoosh, Alireza Biglari, Rahim Sorouri, Fatemeh Ashrafian, Mona Sadat Larijani, Vicente Verez-Bencomo, Maria Eugenia Toledo-Romani, Carmen Valenzuela Silva, Mostafa Salehi-Vaziri, Sarah Dahmardeh, Delaram Doroud, Mohammad Banifazl, Ehsan Mostafavi, Anahita Bavand, Amitis Ramezani
Summary: This study evaluated and compared the efficacy of PastoCovac Plus protein-subunit vaccine with ChAdOx1-S and BBIBP-CorV in volunteers who had been primed with two doses of ChAdOx1-S or BBIBP-CorV vaccines. The results showed that PastoCovac Plus effectively increased specific antibody levels and could be used in heterologous regimens to boost humoral immune responses.
Article
Infectious Diseases
Niko Kohmer, Shivana Stein, Barbara Schenk, Katharina Grikscheit, Melinda Metzler, Holger F. Rabenau, Marek Widera, Eva Herrmann, Sabine Wicker, Sandra Ciesek
Summary: Heterologous COVID-19 vaccination regimens are an alternative to conventional immunization programs and demonstrate lower reactogenicity and higher neutralizing activity over time compared to homologous vaccination with mRNA. A third dose of an mRNA vaccine is necessary to maintain neutralizing activity against SARS-CoV-2 and variants of concern-adapted versions of the vaccines are desired.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Multidisciplinary Sciences
Chih-Jung Chen, Lan-Yan Yang, Wei-Yang Chang, Yhu-Chering Huang, Cheng-Hsun Chiu, Shin-Ru Shih, Chung-Guei Huang, Kuan-Ying A. Huang
Summary: Heterologous prime-boost COVID-19 vaccine strategy can enhance mass immunization. This study demonstrates the early immunogenicity and safety outcomes of heterologous immunization with a viral vector vaccine and a spike-2P subunit vaccine. The results show superior neutralizing antibody titers and enhanced immune cell responses in the heterologous group, supporting the use of this strategy for COVID-19 immunization.
NATURE COMMUNICATIONS
(2022)
Article
Medicine, General & Internal
S. A. Madhi, V Baillie, C. L. Cutland, M. Voysey, A. L. Koen, L. Fairlie, S. D. Padayachee, K. Dheda, S. L. Barnabas, Q. E. Bhorat, C. Briner, G. Kwatra, K. Ahmed, P. Aley, S. Bhikha, J. N. Bhiman, A' E. Bhorat, J. du Plessis, A. Esmail, M. Groenewald, E. Horne, S-H Hwa, A. Jose, T. Lambe, M. Laubscher, M. Malahleha, M. Masenya, M. Masilela, S. McKenzie, K. Molapo, A. Moultrie, S. Oelofse, F. Patel, S. Pillay, S. Rhead, H. Rodel, L. Rossouw, C. Taoushanis, H. Tegally, A. Thombrayil, S. van Eck, C. K. Wibmer, N. M. Durham, E. J. Kelly, T. L. Villafana, S. Gilbert, A. J. Pollard, T. de Oliveira, P. L. Moore, A. Sigal, A. Izu
Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
P. Maclean, A. J. Mentzer, T. Lambe, J. C. Knight
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
(2023)
Article
Immunology
Sarah Fidler, Julie Fox, Timothy Tipoe, Stephanie Longet, Tom Tipton, Movin Abeywickrema, Sandra Adele, Jasmini Alagaratnam, Mohammad Ali, Parvinder K. Aley, Suhail Aslam, Anbhu Balasubramanian, Anna Bara, Tanveer Bawa, Anthony Brown, Helen Brown, Federica Cappuccini, Sophie Davies, Jamie Fowler, Leila Godfrey, Anna L. Goodman, Kathrine Hilario, Carl-Philipp Hackstein, Moncy Mathew, Yama F. Mujadidi, Alice Packham, Claire Petersen, Emma Plested, Katrina M. Pollock, Maheshi N. Ramasamy, Hannah Robinson, Nicola Robinson, Patpong Rongkard, Helen Sanders, Teona Serafimova, Niamh Spence, Anele Waters, Danielle Woods, Panagiota Zacharopoulou, Eleanor Barnes, Susanna Dunachie, Philip Goulder, Paul Klenerman, Alan Winston, Adrian V. S. Hill, Sarah C. Gilbert, Miles Carroll, Andrew J. Pollard, Teresa Lambe, Ane Ogbe, John Frater
Summary: People with HIV on antiretroviral therapy and good CD4 T-cell counts can generate effective immune responses against SARS-CoV-2 after vaccination. A third vaccine dose can significantly enhance B- and T-cell immunity, including responses to known variants of concern.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Immunology
Merryn Voysey, Amy Flaxman, Jeremy Aboagye, Parvinder K. Aley, Sandra Belij-Rammerstorfer, Sagida Bibi, Mustapha Bittaye, Federica Cappuccini, Sue Charlton, Elizabeth A. Clutterbuck, Sophie Davies, Christina Dold, Nick J. Edwards, Katie J. Ewer, Saul N. Faust, Pedro M. Folegatti, Jamie Fowler, Ciaran Gilbride, Sarah C. Gilbert, Leila Godfrey, Bassam Hallis, Holly E. Humphries, Daniel Jenkin, Simon Kerridge, Yama F. Mujadidi, Emma Plested, Maheshi N. Ramasamy, Hannah Robinson, Helen Sanders, Matthew D. Snape, Rinn Song, Kelly M. Thomas, Marta Ulaszewska, Danielle Woods, Daniel Wright, Andrew J. Pollard, Teresa Lambe
Summary: Two doses of ChAdOx1 nCov-19 vaccine generate persistent spike-specific IgG antibody responses for at least 1 year and potentially up to 2 years. This immune response is associated with a reduced risk of serious disease and hospitalization. Vaccine effectiveness declines over time based on the trajectory of immune responses following the primary dose series.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2023)
Article
Infectious Diseases
James Nyagwange, Bernadette Kutima, Kennedy Mwai, Henry K. Karanja, John N. Gitonga, Daisy Mugo, Yiakon Sein, Daniel Wright, Donwilliams O. Omuoyo, Joyce U. Nyiro, James Tuju, D. James Nokes, Ambrose Agweyu, Philip Bejon, Lynette I. Ochola-Oyier, J. Anthony G. Scott, Teresa Lambe, Eunice Nduati, Charles Agoti, George M. Warimwe
Summary: The study found evidence of pre-existing functional humoral responses to SARS-CoV-2 in Kilifi, coastal Kenya, which aligns with findings of pre-existing immunity to COVID-19 in other regions.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Cell Biology
William S. Foster, Joseph Newman, Nazia Thakur, Alexandra J. Spencer, Sophie Davies, Danielle Woods, Leila Godfrey, Sarah H. Ross, Hayley J. Sharpe, Arianne C. Richard, Dalan Bailey, Teresa Lambe, Michelle A. Linterman
Summary: Effective vaccines have reduced the impact of SARS-CoV-2 infection, but the elderly are still at high risk. Understanding vaccine-induced immunity and how it changes with age is important for future vaccine development. CD8(+) T cells play a crucial role in killing infected cells, and vaccines that stimulate both CD8(+) T cell responses and humoral immunity provide additional protection, especially in older individuals. The study shows that the ChAdOx1 nCoV-19 vaccine generates a good CD8(+) T-cell response in older mice, but age-related differences in T-cell characteristics are observed.
IMMUNOLOGY AND CELL BIOLOGY
(2023)
Article
Immunology
Paulina Kaplonek, Deniz Cizmeci, Gaurav Kwatra, Alane Izu, Jessica Shih-Lu Lee, Harry L. Bertera, Stephanie Fischinger, Colin Mann, Fatima Amanat, Wenjun Wang, Anthonet L. Koen, Lee Fairlie, Clare L. Cutland, Khatija Ahmed, Keertan Dheda, Shaun L. Barnabas, Qasim Ebrahim Bhorat, Carmen Briner, Florian Krammer, Erica Ollman Saphire, Sarah C. Gilbert, Teresa Lambe, Andrew J. Pollard, Marta Nunes, Manfred Wuhrer, Douglas A. Lauffenburger, Shabir A. Madhi, Galit Alter
Summary: Despite the success of COVID-19 vaccines, breakthrough infections can occur due to SARS-CoV-2 variants. The immune mediators of protection in humans are still unknown. A study on ChAdOx1 nCoV-19 (AZD1222) vaccine recipients in South Africa found different Fc-receptor-binding antibodies among different groups. Individuals who resisted COVID-19 exclusively had Fc gamma R3B-binding antibodies, while those who experienced breakthrough had enhanced IgA and IgG3 with enriched Fc gamma R2B binding. Antibodies unable to bind to Fc gamma R3B led to immune complex clearance and inflammation. The differential antibody binding to Fc gamma R3B was associated with Fc-glycosylation differences in SARS-CoV-2-specific antibodies.
Article
Immunology
Anthonet L. Koen, Alane Izu, Vicky Baillie, Gaurav Kwatra, Clare L. Cutland, Lee Fairlie, Sherman D. Padayachee, Keertan Dheda, Shaun L. Barnabas, Qasim Ebrahim Bhorat, Carmen Briner, Khatija Ahmed, Sutika Bhikha, Jinal N. Bhiman, Jeanine du Plessis, Aliasgar Esmail, Elizea Horne, Shi-Hsia Hwa, Aylin Oommen-Jose, Teresa Lambe, Matt Laubscher, Mookho Malahleha, Gabriella Benade, Shakeel McKenzie, Suzette Oelofse, Faeezah Patel, Sureshnee Pillay, Sarah Rhead, Hylton Rodel, Carol Taoushanis, Houriiyah Tegally, Asha Thombrayil, Tonya L. Villafana, Sarah Gilbert, Andrew J. Pollard, Shabir A. Madhi
Summary: The final analysis of the COV005 study in South African adults showed that the efficacy of the AZD1222 vaccine varied against different SARS-CoV-2 variants. The vaccine had high efficacy against the wild type virus, but lower efficacy against the Beta and Delta variants. Safety was consistent with previous findings.
Letter
Microbiology
Peter Speck, Jason Mackenzie, Rowena A. Bull, Barry Slobedman, Heidi Drummer, Johanna Fraser, Lara Herrero, Karla Helbig, Sarah Londrigan, Gregory Moseley, Natalie Prow, Grant Hansman, Robert Edwards, Chantelle Ahlenstiel, Allison Abendroth, David Tscharke, Jody Hobson-Peters, Robson Kriiger-Loterio, Rhys Parry, Glenn Marsh, Emma Harding, David A. Jacques, Matthew J. Gartner, Wen Shi Lee, Julie McAuley, Paola Vaz, Frank Sainsbury, Michelle D. Tate, Jane Sinclair, Allison Imrie, Stephen Rawlinson, Andrew Harman, Jillian M. Carr, Ebony A. Monson, Merilyn Hibma, Timothy J. Mahony, Thomas Tu, Robert J. Center, Lok Bahadur Shrestha, Robyn Hall, Morgyn Warner, Vernon Ward, Danielle E. Anderson, Nicholas S. Eyre, Natalie E. Netzler, Alison J. Peel, Peter Revill, Michael Beard, Alistair R. Legione, Alexandra J. Spencer, Adi Idris, Jade Forwood, Subir Sarker, Damian F. J. Purcell, Nathan Bartlett, Joshua M. Deerain, Bruce J. Brew, Sassan Asgari, Helen Farrell, Alexander Khromykh, Daniel Enosi Tuipulotu, David Anderson, Sevim Mese, Yaman Tayyar, Kathryn Edenborough, Jasim Muhammad Uddin, Abrar Hussain, Connor J. Daymond, Jacinta Agius, Karyn N. Johnson, Paniz Shirmast, Mahdi Abedinzadeshahri, Robin MacDiarmid, Caroline L. Ashley, Jay Laws, Lucy L. Furfaro, Thomas D. Burton, Stephen M. R. Johnson, Zahra Telikani, Mary Petrone, Justin A. Roby, Carolyn Samer, Andreas Suhrbier, April van der Kamp, Anthony Cunningham, Celeste Donato, Jackie Mahar, Wesley D. Black, Subhash Vasudevan, Roman Lenchine, Kirsten Spann, Daniel J. Rawle, Penny Rudd, Jessica Neil, Richard Kingston, Timothy P. Newsome, Ki Wook Kim, Johnson Mak, Kym Lowry, Nathan Bryant, Joanne Meers, Jason A. Roberts, Nigel McMillan, Larisa I. Labzin, Andrii Slonchak, Leon E. Hugo, Bennett Henzeler, Natalee D. Newton, Cassandra T. David, Patrick C. Reading, Camille Esneau, Tatiana Briody, Najla Nasr, Donna McNeale, Brian McSharry, Omid Fakhri, Bethany A. Horsburgh, Grant Logan, Paul Howley, Paul Young
Article
Cell Biology
Zixi Yin, Ji-Li Chen, Yongxu Lu, Beibei Wang, Leila Godfrey, Alexander J. Mentzer, Xuan Yao, Guihai Liu, Dannielle Wellington, Yiqi Zhao, Peter A. C. Wing, Wanwisa Dejnirattisa, Piyada Supasa, Chang Liu, Philip Hublitz, Ryan Beveridge, Craig Waugh, Sally-Ann Clark, Kevin Clark, Paul Sopp, Timothy Rostron, Juthathip Mongkolsapaya, Gavin R. Screaton, Graham Ogg, Katie Ewer, Andrew J. Pollard, Sarah Gilbert, Julian C. Knight, Teresa Lambe, Geoffrey L. Smith, Tao Dong, Yanchun Peng
Summary: This study evaluates T cell responses in recovered COVID-19 patients and vaccinated donors using recombinant vaccinia virus (rVACV) expression of SARS-CoV-2 spike protein and SARS-CoV-2 infection of ACE-2-transduced B cell lines. The results show that rVACV expression of SARS-CoV-2 antigen can be used to assess T cell responses to naturally processed spike antigens. The rVACV system can also be used to evaluate cross-reactivity of memory T cells to variants of concern and identify epitope escape mutants.
Article
Biotechnology & Applied Microbiology
Marta Ulaszewska, Sarah Merelie, Sarah Sebastian, Teresa Lambe
Summary: Herpes zoster (HZ) can be prevented by vaccination with recombinant HZ vaccine or live HZ vaccine, but vaccine efficacy declines with age and live HZ vaccine is contraindicated for immunosuppressed individuals. A nonreplicating chimpanzee adenovirus (ChAd) vector encoding VZV envelope glycoprotein E (ChAdOx1-VZVgE) showed higher T cell responses compared to recombinant HZ vaccine or live HZ vaccine in mice. Antibody responses were higher with recombinant HZ vaccine. ChAdOx1-VZVgE could boost T cell and antibody responses after live HZ vaccine priming. Polyfunctional T cells expressing multiple cytokines were more frequent with ChAdOx1-VZVgE. These findings support the clinical development of ChAdOx1-VZVgE for HZ prevention in adults aged 50 years or over.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Immunology
Anna Schmidt, Basudev Paudyal, Sonia Villanueva-Hernandez, Adam Mcnee, Eleni Vatzia, Brigid Veronica Carr, Selma Schmidt, Amy Mccarron, Veronica Martini, Silke Schroedel, Christian Thirion, Ryan Waters, Francisco J. Salguero, Wilhelm Gerner, Matthias Tenbusch, Elma Tchilian
Summary: Mucosal delivery of adenoviral vectors expressing HA and NP proteins did not provide sufficient protection against heterologous H3N2 challenge in pigs, despite strong T-cell responses. Co-delivery of IL-1 beta increased lung pathology without affecting viral load. These findings suggest caution in extrapolating results from animal models to humans.
FRONTIERS IN IMMUNOLOGY
(2023)
Letter
Microbiology
Peter Speck, Jason Mackenzie, Rowena A. Bull, Barry Slobedman, Heidi Drummer, Johanna Fraser, Lara Herrero, Karla Helbig, Sarah Londrigan, Gregory Moseley, Natalie Prow, Grant Hansman, Robert Edwards, Chantelle Ahlenstiel, Allison Abendroth, David Tscharke, Jody Hobson-Peters, Robson Kriiger-Loterio, Rhys Parry, Glenn Marsh, Emma Harding, David A. Jacques, Matthew J. Gartner, Wen Shi Lee, Julie McAuley, Paola Vaz, Frank Sainsbury, Michelle D. Tate, Jane Sinclair, Allison Imrie, Stephen Rawlinson, Andrew Harman, Jillian M. Carr, Ebony A. Monson, Merilyn Hibma, Timothy J. Mahony, Thomas Tu, Robert J. Center, Lok Bahadur Shrestha, Robyn Hall, Morgy Warner, Vernon Ward, Danielle E. Anderson, Nicholas S. Eyre, Natalie E. Netzler, Alison J. Peel, Peter Revill, Michael Beard, Alistair R. Legione, Alexandra J. Spencer, Adi Idris, Jade Forwood, Subir Sarker, Damian F. J. Purcell, Nathan Bartlett, Joshua M. Deerain, Bruce J. Brew, Sassan Asgari, Helen Farrell, Alexander Khromykh, Daniel Enosi Tuipulotu, David Anderson, Sevim Mese, Yaman Tayyar, Kathryn Edenborough, Jasim Muhammad Uddin, Abrar Hussain, Connor J. I. Daymond, Jacinta Agius, Karyn N. Johnson, Paniz Shirmast, Mahdi Abedinzadeshahri, Robin MacDiarmid, Caroline L. Ashley, Jay Laws, Lucy L. Furfaro, Thomas D. Burton, Stephen M. R. Johnson, Zahra Telikani, Mary Petrone, Justin A. Roby, Carolyn Samer, Andreas Suhrbier, April van der Kamp, Anthony Cunningham, Celeste Donato, Jackie Mahar, Wesley D. Black, Subhash Vasudevan, Roman Lenchine, Kirsten Spann, Daniel J. Rawle, Penny Rudd, Jessica Neil, Richard Kingston, Timothy P. Newsome, Ki Wook Kim, Johnson Mak, Kym Lowry, Nathan Bryant, Joanne Meers, Jason A. Roberts, Nigel McMillan, Larisa I. Labzin, Andrii Slonchak, Leon E. Hugo, Bennett Henzeler, Natalee D. Newton, Cassandra T. David, Patrick C. Reading, Camille Esneau, Tatiana Briody, Najla Nasr, Donna McNeale, Brian McSharry, Omid Fakhri, Bethany A. Horsburgh, Grant Logan, Paul Howley, Paul Young
Article
Multidisciplinary Sciences
Hailey R. Hornsby, Alexander R. Nicols, Stephanie Longet, Chang Liu, Adriana Tomic, Adrienn Angyal, Barbara K. Kronsteiner, Jessica K. Tyerman, Tom Tipton, Peijun Zhang, Marta Gallis, Piyada Supasa, Muneeswaran Selvaraj, Priyanka Abraham, Isabel Neale, Mohammad A. Ali, Natalie M. Barratt, Jeremy Nell, Lotta Gustafsson, Scarlett Strickland, Irina Grouneva, Timothy C. Rostron, Shona M. Moore, Luisa L. Hering, Susan L. Dobson, Sagida Bibi, Juthathip Mongkolsapaya, Teresa Lambe, Dan Wootton, Victoria Hall, Susan Hopkins, Tao Dong, Eleanor Barnes, Gavin Screaton, Alex Richter, Lance Turtle, Sarah L. Rowland-Jones, Miles Carroll, Christopher J. A. Duncan, Paul Klenerman, Susanna J. Dunachie, Rebecca P. Payne, Thushan de Silva
Summary: The authors characterized the immune response in vaccinated individuals infected with the Omicron variant and observed immune enhancement. They found that increases in neutralizing antibodies and spike T cells were stronger in individuals with no previous infection, while mucosal antibodies and non-spike responses increased regardless of infection history. The findings suggest that hybrid immunity induced by Omicron breakthrough infections can provide significant immune enhancement to protect against future variants.
NATURE COMMUNICATIONS
(2023)
Article
Medicine, General & Internal
Jack E. Saunders, Ciaran Gilbride, Stuart Dowall, Susan Morris, Marta Ulaszewska, Alexandra J. Spencer, Emma Rayner, Victoria A. Graham, Emma Kennedy, Kelly Thomas, Roger Hewson, Sarah C. Gilbert, Sandra Belij-Rammerstorfer, Teresa Lambe
Summary: In this study, a preclinical assessment of a chimpanzee adenoviral vectored vaccine (ChAdOx2 CCHF) against Crimean-Congo Haemorrhagic Fever virus (CCHFV) was conducted. The results showed that ChAdOx2 CCHF vaccine induced both cellular and humoral immune responses in mice and provided 100% protection in a lethal CCHF challenge model. Additionally, the combination of ChAdOx2 CCHF vaccine with Modified Vaccinia Ankara vaccine (MVA CCHF) elicited the highest levels of CCHFV-specific cell-mediated and antibody responses in mice.
